Seoul: SK bioscience Co., a biopharmaceutical arm of South Korea's SK Group, on Tuesday reported its 2025 net loss of 56.2 billion won (US$38.9 million), remaining in the red compared with the previous year. The announcement highlights the financial challenges the company continues to face.

According to Yonhap News Agency, the company stated in a regulatory filing that it continued to post an operating loss of 123.5 billion won for the year, a slight improvement compared with a loss of 138.4 billion won a year earlier. Despite these losses, the company's revenue saw a significant increase, rising 143.5 percent to 651.4 billion won.